Pharmaceutical company IBSA UK&I have just launched a new, clinically supported injectable to provide early intervention to the commonly underdiagnosed and undertreated condition of Peyronie’s Disease affecting men. 

 

This new drug, Perovial®, is indicated for the management of Peyronie’s Disease during the acute phase and is the first licensed hyaluronic acid injectable for the earlier stages of the condition. 

What is Peyronie’s Disease? 

Peyronie’s Disease is caused by fibrous scar tissue (or plaque) that develops under the skin of the penis. This leads to significant curvature, pain, and, in some cases, erectile dysfunction. 

 

There are usually two phases to this condition. The first is the acute phase, presenting with pain and changing curvature. The second is the chronic phase where the plaque hardens, the curve stabilizes, and pain often subsides.

 

Peyronie’s is treatable. It is important to seek early evaluation by a urologist or andrologist, as treatment is more effective when begun in the early stages.

 

You can read more about Peyronie’s Disease here. 

 

New Treatment for Peyronie’s Disease

For patients in the acute phase of Peyronie’s, this new drug Perovial® can be a brilliant evidence-based option for treatment, providing healthcare professionals with a way to treat Peyronie’s in the early stages. 

 

There has historically been a gap in treatment, but with Perovial® the Andrologists and Urologists at London Men’s Clinic are confident that they can address this and make a real difference to their patients.

 

Many men suffering with Peyronie’s struggle with their quality of life, but this new licensed injectable provides a meaningful treatment option in the acute phase of the condition. It’s vital that patients seek the help of an Andrologist or Urologist at the onset of symptoms to try and prevent as much scarring and deformity as possible. 

 

 

How is this new treatment for Peyronie’s Disease administered?

Over the course of a 10-12 week treatment period, Perovial® is delivered via intrapenile injection. 

 

How does Perovial® work to treat Peyronie’s Disease? 

 

The injectable is formulated from hyaluronic acid which has antioxidative and antifibrotic properties. The aim of the injectable is to:

  • Soften plaque
  • Support the remodelling of tissue 
  • Help to slow the progression of scarring

 

Does Perovial® work for treating acute phase Peyronie’s Disease?

 

Clinical studies* on the use of Perovial® have reported improvements in: 

  • Penile curvature
  • Plaque size 
  • Erectile function

 

Alongside the benefits above, patient reactions to the treatment have been favourable. Research also suggests a tolerable safety profile.

 

*The clinical studies are:

  • Favilla, V. et al. (2017). Andrology, 5(4), pp.771–775.
  • Cocci, A. et al. (2021). World Journal of Men’s Health, 39(2), p.352.
  • Zucchi, A. et al. (2016). Sexual Medicine, 4(2), pp.e85–e90.

London Men’s Clinic now offering new treatment for the early stages of Peyronie’s Disease

The team of Andrologists and Urologists here at London Men’s Clinic are delighted to be able to offer their patients this new treatment. 

 

We are excited to be able to offer patients a structured intervention pathway for the acute phase of Peyronie’s Disease, and urge anyone struggling in silence with symptoms to get in touch with our team today.